You decide for yourself. EDGX knows this stock will move up very, very soon. They continue to show big sell orders to force the stock down for their own accumulation. The results will be known this summer not in December.
Primary Outcome Measures:
To determine safety and the effect of intracoronary infusion of AMR-001 on myocardial perfusion (RTSS), measured by gated SPECT MPI at baseline and six months in subjects post-STEMI [ Time Frame: primary outcome measured at 6 months ] [ Designated as safety issue: Yes ]
primary endpoint includes safety of bone marrow procurement (measured by adverse events) and AMR-001 cell infusion (including incidence of re-stenosis and stent thrombosis in addition to other adverse events)as well as efficacy measured by quantitative by gated SPECT MPI specifically looking at resting total severity score)
Estimated Enrollment: 160
Study Start Date: December 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)